personally I think that’s extremely realistic,should the company succeed in commercialising the EFTI -Pembro combo in lung cancer,possibly making it the new SOC.
”New and IMPORTANT data to be released in q4”
”This data along with the feedback from the regulatory authoritative will help shape this ph 3 trial “
Just my take but I think having the ability in some cases to replace chemo , would lead to at the very least fast track approval , if not breakthrough designation ,accelerated approval or perhaps even priority review.
Gues we’re soon about to find out.Anything greater than fast track , May encourage Merck to act sooner rather than later.Well done Marc I think you’ve just about reached the sweet spot to achieve optimum deal outcomes.
Ann: Immutep Investor Update, page-42
Add IMM (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
35.5¢ |
Change
0.015(4.41%) |
Mkt cap ! $515.6M | |||
| Open | High | Low | Value | Volume |
| 34.0¢ | 36.0¢ | 34.0¢ | $1.270M | 3.611M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 7 | 286261 | 35.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 36.0¢ | 253490 | 7 |
View Market Depth
| Last trade - 16.10pm 16/08/2024 (20 minute delay) ? |
| IMM (ASX) Chart |